Abstract
Introduction
Among various co-infections incriminated in human immunodeficiency virus (HIV)-associated pathology, Helicobacter pylori plays an important, but under-investigated part. Many HIV-infected patients have dyspeptic complaints and, though there is a recognized association between Helicobacter pylori and peptic ulcer among general population (1), the etiology of gastro-intestinal disorders varies greatly among HIV-positive subjects, ranging from opportunistic infections (2, 3) to medication adverse effects (4) .
Several studies disputed over the prevalence of Helicobacter pylori infection among HIV-positive persons, reported to be either similar to (5, 6) or lower than the prevalence of the same infection in the general population (2, 7) . Those depicting lower Helicobacter pylori infection rates among HIV-positive subjects incriminate the frequent use of antibiotics for opportunistic infections in severely immunocompromised patients, responsible for the accidental eradication of Helicobacter pylori (2) . Besides, hypochlorhydria described in HIV-positive patients by several authors (8, 9) may favor the development of various digestive opportunistic pathogens, competing with Helicobacter pylori for gastro-intestinal sites of infection (2) .
Meanwhile, other researchers (2, 5) investigated the role played by the level of CD4+ T-cells in the acquisition of Helicobacter pylori infection. Lower prevalence of Helicobacter pylori infection was noticed at CD4+ T-lymphocyte levels below 200cells/µL (5) . Other studies depicted a reduction in the frequency of Helicobacter pylori infection among severely immunosuppressed patients, with acquired immunodeficiency syndrome (AIDS) (2, 3, 5, (10) (11) (12) (13) .
Research examining the relationship between HIV-RNA plasma viral load (VL) and the presence of Helicobacter pylori has been rather poor, with reports of no statistically significant differences between HIV-RNA plasma VL among Helicobacter pylori positive and negative subjects (2) .
Although research was performed in various countries around the globe, Helicobacter pylori -HIV co-infection has not been sufficiently investigated in our geographic area, which provides space for the present study. 
Results
Five (11.36%) HIV-infected patients in group A and eight (13.79%) HIV-negative subjects from group B tested positive for Helico-
The main purpose of this study was to assess the frequency of Helicobacter pylori infection among HIV-positive patients with dyspeptic complaints, compared to the HIV-negative population with similar symptoms. Secondary objectives were to investigate the importance of various factors associated with the presence of this microorganism in HIV-positive patients: the level of CD4+ T-lymphocytes, HIV-RNA plasma viral load, recent antibiotic treatment and the influence of antiretroviral therapy.
Methods
We performed a retrospective, analytical, case-control study, over a period of 26 months (November 2011 -December 2013), upon two groups of patients with dyspeptic symptoms (nausea, vomiting, upper abdominal pain, pyrosis) tested for Helicobacter pylori stool antigen at the Infectious Diseases Laboratory, Clinical County Hospital Mureş. Inclusion criteria were: the presence of dyspeptic symptoms -epigastric pain, nausea, vomiting, pyrosis -and adult age -over 18 years, while exclusion criteria were the lack of symptoms and pediatric age, under 18 years.
Group A consisted of 44 HIV-infected patients, while 58 HIV-negative subjects formed group B. The two groups were similar from the point of view of demographic features; age, gender and environment distribution. Figure 1 )
According to the result of Helicobacter pylori stool antigen test, HIV-infected patients in group A formed two subgroups: A1, consisting of 5 Helicobacter pylori-positive subjects and A2 -39 Helicobacter pylori-negative individuals. The general characteristics of both subgroups are depicted in Table II .
We did not find statistically significant differences between the two subgroups regarding demographic features. Median age was 23 years in subgroup A1 and 24 years in subgroup A2 (p=0.59). Gender distribution was 60% male: 40% female in subgroup A1 and 53.85% male: 46.15% female in subgroup A2. Environment distribution was 60% urban: 40% rural in subgroup A1 and 43.69% urban: 56.41% rural in subgroup A2 (p=0.64).
Two (40%) subgroup A1 and 19 (48.72%) subgroup A2 subjects had attended only primary school. All patients in subgroup A1 and 30 Table I (Figure 2) Median HIV-ARN plasma viral load was undetectable in subgroup A1 and registered a level of 2.65 log in subgroup A2 (p=0.52). (Figure 3 Analyzing the number of hospitalizations within the previous 12 months, we registered a median of 3 in subgroup A1 and 2 in subgroup A2 (p=0.89), while the median number of hospitalizations during the previous 5 years was 5 in subgroup A1 and 7 in subgroup A2 (p=0.89).
. Demographic characteristics of groups A (HIV-positive patients) and B (HIV-negative patients).

Characteristic
HIV-positive patients (group A): n (%)
HIV-negative patients (group B): n (%) P-value
Four (80%) subgroup A1 and 33 (84.6%) subgroup A2 patients had undergone antibiotic therapy for various infectious co-morbidities within the previous 6 months, including antimicrobial substances effective against Helicobacter pylori. We did not register any statistically significant association between recent antibiotic therapy prescribed for extra-digestive indications and the presence of Helicobacter pylori
Figure 2. Helicobacter pylori infection and CD4+ T-lymphocytes level in HIV-infected patients
infection. 3 (60%) subgroup A1 and 26 (66.6%) subgroup A2 subjects were under antiretroviral therapy (ARVT) -we did not register any statistically significant association between ARVT and the presence of Helicobacter pylori.
Both subgroup A1 and A2 patients suffered from various infectious co-morbidities. Bacterial infections were diagnosed in 4 (80%) subgroup A1 subjects and 33 (84.6%) subgroup A2 patients. We did not register fungal or parasitic infections in subgroup A1 patients, while 3 (7.6%) subgroup A2 individuals were suffering from fungal illnesses and 4 (10.2%) of them from parasitic diseases. Mycobacterial infections were detected in 2 (40%) subgroup A1 and 9 (23.0%) subgroup A2 patients (p=0.58).
HIV-infected patients in both subgroups also experienced independent risk factors for digestive illnesses, irrespective of Helicobacter pylori infection. Three (60%) Helicobacter pylori-positive patients and 23 (58.9%) Helicobacter pylori-negative ones were smokers. All 5 Helicobacter pylori-positive patients in subgroup A1 denied alcohol consumption, while 13 (33.3%) admitted frequently drinking alcohol (p=0.30). All subjects in both subgroups denied narcotics abuse. Two (40%) subgroup A1 and 22 (56.4%) subgroup A2 patients were receiving steroids / non-steroidal anti-inflammatory medication (NSAIDs), prescribed for associated illnesses (p=0.64).
Discussion
Although the role of Helicobacter pylori in the pathogenesis of gastro-intestinal disorders -gastritis, peptic ulcer, gastric adenocarcinoma and mucosa-associated (MALT)-lymphoma -in the general population is well-known (1), the impact of this infection upon digestive pathology in HIV-positive hosts has not been extensively examined, so far. Considering the inhomogeneous literature data and the relatively sparse information regarding our geographic area, our study aimed at establishing the frequency of Helicobacter pylori infection in HIV-positive compared to HIV-negative individuals with dyspeptic symptoms, as well as investigating various factors possibly correlated to its presence.
Our primary group of study consisted of 44 HIV-infected patients with dyspeptic symptoms, to which we paired a second group formed by 58 HIV-negative subjects with similar complaints. Although Helicobacter pylori infection may be asymptomatic, we included in our study only patients with digestive complaints, as we believed they would provide the highest chances for Helicobacter pylori detection. Since most HIV-positive patients in our study were young adults, concurring to the peculiar epidemiologic pattern of HIV infection in our country, it was important not to have statistically significant differences between the two groups (HIV-positive and HIV-negative subjects) regarding age characteristics (p=0.53), as the prevalence of Helicobacter pylori infection is known to vary with age: acquired in infancy in developing regions and during adulthood in industrialized countries (14) .
The diagnostic method of choice in our study -Helicobacter pylori stool antigen detection via qualitative immunochromatographic assay -presented the advantage of non-invasiveness, since HIV-positive patients, frequently subjected to invasive diagnostic or therapeutic procedures for various opportunistic infections and malignant lesions, may prove reluctant to undergoing yet another invasive technique, which implies the discomfort of upper gastro-intestinal endoscopy.
In our study, Helicobacter pylori infection registered a frequency of 11.3% among HIV-positive patients, slightly lower than among HIV-negative subjects -13.7%, but not enough to provide a statistically significant association between the HIV infection and the presence of Helicobacter pylori (p=0.77, OR=0.80). This was similar to the conclusion of some authors (5, 6), but different from others (2) . The geographic area where the study was conducted may have significance. It is well known that Helicobacter pylori infection rates are higher in developing countries than in industrialized regions, related to socio-economic factors, level of hygiene, overcrowding, living conditions, education (14, 15) . The diagnostic method of use may also be relevant, since several authors based their studies upon invasive diagnostic methods (2, 3) , while other research was conducted using molecular diagnostic methods (6) . In order to extend our study and better relate to literature data, the patients' accept to undergo upper gastro-intestinal endoscopy would be welcome.
The absence of a statistically significant difference regarding the frequency of Helicobacter pylori infection in HIV-positive and HIV-negative patients opens the gate for exploring other causes for dyspepsia in HIV-infected persons, ranging from fungal and viral digestive infections (3) to medication adverse effects (4), as some authors state than more than half of all HIV-positive individuals complain of gastro-intestinal symptoms (16) .
Although it has been hypothesized that poor education, including incorrect sanitary practices, might indirectly influence the presence of Helicobacter pylori (14), we did not register statistically significant differences regarding the level of education (p=1.00) or lack of employmentmeasure of the socio-economic status (p=0.56) between subgroups A1 and A2. This could be explained by the high rates of unemployment and incomplete education among both subgroups of HIV-infected patients from our geographic area.
Among HIV-positive patients in our study, those infected with Helicobacter pylori registered slightly higher levels of CD4+ T-lymphocytes (median 661 cells/µL) than those who tested negative for Helicobacter pylori infection (median 273 cells/µL), although this did not result in a statistically significant difference (p=0.32). This may be explained by the fact that poor immune status, reflected mainly by low CD4+ T-lymphocytes levels, favors the onset of opportunistic infections, some with gastro-intestinal location (17) , thus competing against Helicobacter pylori for the same site of infection, as well as it increases the need of antibiotics, possibly leading to the accidental eradication of Helicobacter pylori (2) . However, in order to achieve a statistically significant conclusion, we need to extend our research, increasing the number of studied patients.
Some studies depicted lower prevalence of Helicobacter pylori infection in patients with CD4+ T-cells < 200 cells/µL (5) and in AIDSstage subjects (5, 10-13). We did not find statistically significant associations between AIDS or C3 stage of HIV infection and the presence of Helicobacter pylori. However, there was a negative (OR=0.40), though not statistically significant association between CD4+ T-lymphocytes level < 200 cells/µL and Helicobacter pylori infection, which concurs to the tendency described in literature (2, 5) .
As for the level of HIV-RNA plasma VL, we registered lower values among Helicobacter pylori-positive patients (median -undetectable) than among Helicobacter pylori-negative ones (median 2.65 log), although we did not find statistically significant difference between the two groups. This resembles other literature data (2), which did not report statistically significant differences between Helicobacter pylori-positive and -negative patients regarding the level of HIV-RNA plasma viral load.
The number of previous hospitalizations did not differ in a statistically significant way between subgroups A1 and A2, whether they were counted during the previous 12 months or 5 years, although most hospitalizations were caused by infectious co-morbidities and one would be tempted to think that antibiotic treatment undergone by these patients during hospitalization could have led to the eradication of Helicobacter pylori. Neither did we find statistically significant difference between Helicobacter pylori-positive and -negative patients regarding the use of antibiotics during the previous 6 months, similar to some literature data (2) . Patients in both subgroups had high rates of antibiotic treatment, connected to high frequency of bacterial infections, possibly correlated to the high number of AIDS-stage subjects registered in both Helicobacter pylori-positive and -negative categories from our study. As supplementary research opportunity, we suggest analyzing the route of administration of antibiotic treatment, as oral versus parenteral route may offer different access to the digestive site of Helicobacter pylori infection.
Another interesting issue would be the association between highly active antiretroviral therapy (HAART) and the presence of Helicobacter pylori, as the main purpose of antiretroviral therapy is to inhibit viral replication, leading to an increase in the level of CD4+ T-lymphocytes and decrease of HIV-RNA plasma viral load, thus reducing the risk of opportunistic infections and the need for antibiotic therapy. However, our study did not reveal a statistically significant difference between antiretroviral treatment and the presence of Helicobacter pylori, similar to other literature data (2).
As we review the somehow poor statistical differences between subgroups A1 and A2, we must consider the presence of independent risk factors for digestive illnesses in both studied subgroups, at similar and usually high rates: smoking, alcohol abuse (p=0.30), anti-inflammatory medication (p=0.64), factors which are known to impact upon the state of the gastro-intestinal tract of the general population (18) . Apart from this, there are studies suggesting an increase in number of non-HIV-associated digestive illnesses in HIV-infected patients during the "HAART era", concomitant to a decrease in the frequency of opportunistic infections in patients under antiretroviral therapy (19) .
While research is needed upon larger groups of patients, adding invasive diagnostic methods, in order to clarify potentially diverging results between our study and other authors' conclusions, one must bear in mind geographic region differences among various groups of study.
